

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A condensation aerosol for delivery of a drug selected from the group consisting of acetaminophen, orphenadrine and tramadol, wherein the condensation aerosol is formed by heating a thin layer containing the drug, on a solid support, to produce a vapor of the drug, and condensing the vapor to form a condensation aerosol characterized by less than 10 % drug degradation products by weight, and an MMAD of less than 5 microns.

2. (previously presented) The condensation aerosol according to Claim 1, wherein the condensation aerosol is formed at a rate greater than 10^9 particles per second.

3. (previously presented) The condensation aerosol according to Claim 2, wherein the condensation aerosol is formed at a rate greater than 10^{10} particles per second.

4.-9. (cancelled)

10. (previously presented) A method of producing a drug selected from the group consisting of acetaminophen, orphenadrine and tramadol in an aerosol form comprising:

a. heating a thin layer containing the drug, on a solid support, to produce a vapor of the drug, and

b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 10% drug degradation products by weight, and an MMAD of less than 5 microns.

11. (previously presented) The method according to Claim 10, wherein the condensation aerosol is formed at a rate greater than 10^9 particles per second.

12. (previously presented) The method according to Claim 11, wherein the

condensation aerosol is formed at a rate greater than 10^{10} particles per second.

13.-18. (cancelled)

19. (previously presented) The condensation aerosol according to Claim 1, wherein the condensation aerosol is characterized by an MMAD of 0.2 to 5 microns.

20. (previously presented) The condensation aerosol according to Claim 1, wherein the condensation aerosol is characterized by an MMAD of less than 3 microns.

21. (currently amended) The condensation aerosol according to Claim 19, wherein the condensation aerosol is characterized by an MMAD of 0.2 ~~and to~~ 3 microns.

22. (currently amended) The condensation aerosol according to Claim 1, wherein the condensation aerosol is characterized by less than 5% drug ~~ester~~ degradation products by weight.

23. (currently amended) The condensation aerosol according to Claim 22, wherein the condensation aerosol is characterized by less than 2.5% drug ~~ester~~ degradation products by weight.

24. (previously presented) The condensation aerosol according to Claim 1, wherein the solid support is a metal foil.

25. (previously presented) The condensation aerosol according to Claim 1, wherein the drug is acetaminophen.

26. (previously presented) The condensation aerosol according to Claim 1, wherein the drug is orphenadrine.

27. (previously presented) The condensation aerosol according to Claim 1, wherein the drug is tramadol.

28. (previously presented) The method according to Claim 10, wherein the condensation aerosol is characterized by an MMAD of 0.2 to 5 microns.
29. (previously presented) The method according to Claim 10, wherein the condensation aerosol is characterized by an MMAD of less than 3 microns.
30. (previously presented) The method according to Claim 28, wherein the condensation aerosol is characterized by an MMAD of 0.2 to 3 microns.
31. (currently amended) The method according to Claim 10, wherein the condensation aerosol is characterized by less than 5% drug ~~ester~~ degradation products by weight.
32. (currently amended) The method according to Claim 31, wherein the condensation aerosol is characterized by less than 2.5% drug ~~ester~~ degradation products by weight.
33. (previously presented) The method according to Claim 10, wherein the solid support is a metal foil.
34. (previously presented) The method according to Claim 10, wherein the drug is acetaminophen.
35. (previously presented) The method according to Claim 10, wherein the drug is orphenadrine.
36. (previously presented) The method according to Claim 10, wherein the drug is tramadol.
37. (previously presented) A condensation aerosol for delivery of acetaminophen, wherein the condensation aerosol is formed by heating a thin layer containing acetaminophen, on

a solid support, to produce a vapor of acetaminophen, and condensing the vapor to form a condensation aerosol characterized by less than 5% acetaminophen degradation products by weight, and an MMAD of 0.2 to 3 microns.

38. (previously presented) A condensation aerosol for delivery of orphenadrine, wherein the condensation aerosol is formed by heating a thin layer containing orphenadrine, on a solid support, to produce a vapor of orphenadrine, and condensing the vapor to form a condensation aerosol characterized by less than 5% orphenadrine degradation products by weight, and an MMAD of 0.2 to 3 microns.

39. (previously presented) A condensation aerosol for delivery of tramadol, wherein the condensation aerosol is formed by heating a thin layer containing tramadol, on a solid support, to produce a vapor of tramadol, and condensing the vapor to form a condensation aerosol characterized by less than 5% tramadol degradation products by weight, and an MMAD of 0.2 to 3 microns.

40. (previously presented) A method of producing acetaminophen in an aerosol form comprising:

- a. heating a thin layer containing acetaminophen, on a solid support, to produce a vapor of acetaminophen, and
- b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% acetaminophen degradation products by weight, and an MMAD of 0.2 to 3 microns.

41. (previously presented) A method of producing orphenadrine in an aerosol form comprising:

- a. heating a thin layer containing orphenadrine, on a solid support, to produce a vapor of orphenadrine, and
- b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% orphenadrine degradation products by weight, and an MMAD of 0.2 to 3 microns.

42. (previously presented) A method of producing tramadol in an aerosol form comprising:

a. heating a thin layer containing tramadol, on a solid support, to produce a vapor of tramadol, and

b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% tramadol degradation products by weight, and an MMAD of 0.2 to 3 microns.